Top 5 Drug Type | Count |
---|---|
Bispecific antibody | 3 |
Bispecific T-cell Engager (BiTE) | 2 |
Antibody drug conjugate (ADC) | 1 |
Small molecule drug | 1 |
Top 5 Target | Count |
---|---|
EGFR x c-Met | 2 |
OX40 x PDL1 | 1 |
LAG3 x PD-1 | 1 |
CD3 x ROR1 | 1 |
BCMA x CD3 | 1 |
Mechanism EGFR T790M inhibitors [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date13 Nov 2015 |
Target |
Mechanism EGFR antagonists [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism LAG3 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date03 Aug 2023 |
Sponsor / Collaborator |
Start Date01 Jun 2023 |
Sponsor / Collaborator |
Start Date16 May 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Cizutamig ( BCMA x CD3 ) | Refractory Multiple Myeloma More | Phase 2 Clinical |
Fanastomig ( LAG3 x PD-1 ) | Solid tumor More | Phase 2 Clinical |
Osimertinib mesylate ( EGFR L858R x EGFR T790M x EGFR-Ex19del ) | EGFR-mutated non-small Cell Lung Cancer More | Phase 2 Clinical |
Bafisontamab ( EGFR x c-Met ) | Non-Small Cell Lung Cancer More | Phase 2 |
EMB-09 ( OX40 x PDL1 ) | Advanced Malignant Solid Neoplasm More | Phase 1 |